Hemispherx Biopharma (HEB)
Hemispherx Biopharma News
Hemispherx Biopharma (HEB) Doubles Q Loss to 2c/Share
Street Insider about 22 days agoHemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2012
GlobeNewswire about 22 days agoPHILADELPHIA -- Hemispherx Biopharma (NYSE Amex:HEB) announced its financial results for the three months ended March 31, 2012. The net loss for the period (including non-cash effects) was $2,308,000 or ...
HEMISPHERX BIOPHARMA INC Files SEC form 10-Q, Quarterly Report
about 22 days agoHemispherx testing whether Ampligen boosts FluMist efficacy
about 29 days agoHemispherx Biopharma announces test of Ampligen with FluMist
about 29 days agoHemispherx Biopharma Announces Test of Ampligen(R) With FluMist
GlobeNewswire about 29 days agoPHILADELPHIA -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"), announced that Ampligen(R), an experimental immunotherapeutic, has been nasally administered ...
HEMISPHERX BIOPHARMA INC Files SEC form 8-K/A, Change in Directors or Principal Officers
about 42 days agoHemispherx Publishes Peer-Reviewed Data on an Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies (NABs) Against Recombinant Interferons Versus Natural Human Interferons (IFNs)
GlobeNewswire about 64 days agoIncidence of NABs Induced Against Natural IFNs, Such as Alferon N Injection(R), Was Very Low (<0.2%) and Significantly Less Than for Recombinant IFNs
Hemispherx Biopharma, Inc. to Host 2011 Year End Conference Call on Thursday, March 22, 2012
GlobeNewswire about 70 days agoPHILADELPHIA -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), has scheduled a conference call and audio webcast on Thursday, March 22, 2012 at 10:00 a.m. (Eastern Time). The conference ...
Benzinga's Microcap Movers for Monday March 19, 2012
Benzinga about 71 days agoHemispherx Publishes Data on the Bioactivity of Ampligen(R) in Chronic Fatigue Syndrome ("CFS")
GlobeNewswire about 71 days agoPHILADELPHIA -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced the publication of a peer-reviewed article providing the results from the AMP-516 ...
Hemispherx Biopharma Announces Fiscal 2011 Year Results
GlobeNewswire about 76 days agoPHILADELPHIA -- Hemispherx Biopharma (NYSE Amex:HEB) announced its financial results for the fiscal year ended December 31, 2011. The net loss for 2011's twelve month period (including non-cash effects) ...
Hemispherx (HEB) Reports Q4 Loss of $0.02/Share
Street Insider about 76 days agoHEMISPHERX BIOPHARMA INC Files SEC form 10-K, Annual Report
about 76 days agoGilead Sciences Inc. Fourth Quarter Earnings Sneak Peek
about 120 days agoYou may also be interested in these HEB related companies
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HEB | 0.28 | +0.01 | +3.70% | 36.67M |
| ISIL | 10.84 | +0.40 | +3.83% | 1.322B |
| ISIG | 1.90 | +0.01 | +0.53% | 25.70M |
| ISI | 60.05 | -0.10 | -0.17% | |
| ISH | 18.35 | +0.25 | +1.38% | 130.68M |
| ISCA | 23.99 | +0.54 | +2.30% | 1.085B |
| IPSU | 6.34 | -0.01 | -0.16% | 77.60M |
| IPS | 31.32 | +0.04 | +0.13% | |
| IPN | 22.70 | -0.20 | -0.87% | |
| IPK | 22.62 | +0.14 | +0.62% |
